NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…
Case report and review of a novel chromosomal abnormality in AML patient
A new research paper was published in Genes & Cancer on June 28, 2023, entitled, “A novel t (5; 17) (q35; q21) associated with t